Clinical and laboratory features of in-patients with multiple sclerosis in a university hospital in Tokyo from 1988-2002

Internal Medicine

Volumn 44, Issue 6, 2005, Pages 560-566

  Tanaka, Kortaro ^a   Kujuro, Yuki ^a   Suzuki, Shigeaki ^a   Tanahashi, Norio ^a   Hamada, Junichi ^a   Nogawa, Shigeru ^a   Suzuki, Norihiro ^a  

^a KEIO UNIVERSITY   (Japan)

Author keywords

Clinical features; Laboratory features; Multiple sclerosis; Primary progressive; Relapsing remitting; Secondary progressive

Indexed keywords

GADOLINIUM; IMMUNOGLOBULIN G;

ADULT; ARTICLE; BRAIN STEM INJURY; CLINICAL FEATURE; COHORT ANALYSIS; CONTRAST ENHANCEMENT; DATA ANALYSIS; DISEASE CLASSIFICATION; DISEASE DURATION; DISEASE EXACERBATION; FEMALE; GAIT DISORDER; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; JAPAN; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; ONSET AGE; PATIENT CODING; PROTEIN CEREBROSPINAL FLUID LEVEL; RETROSPECTIVE STUDY; SPINAL CORD LESION; STATISTICAL SIGNIFICANCE; SYMPTOM; UNIVERSITY HOSPITAL; VISUAL DISORDER; WHEELCHAIR;

ADULT; AGE OF ONSET; BRAIN; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HOSPITALS, UNIVERSITY; HUMANS; INCIDENCE; JAPAN; MAGNETIC RESONANCE IMAGING; MALE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; OLIGOCLONAL BANDS; RECURRENCE; RETROSPECTIVE STUDIES; SEX DISTRIBUTION; SPINAL CORD;

EID: 21644475734     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.44.560     Document Type: Article

References (23)

1. Shibasaki H, McDonald WI, Kuroiwa Y. Racial modification of the clinical picture of multiple sclerosis: comparison between British and Japanese patients. J Neurol Sci 49: 253-271, 1981.
2. Kira J. Multiple sclerosis in the Japanese population. Lancet Neurol 2: 117-127, 2003.
3. Kuroiwa Y, Shibasaki H. Epidemiologic and clinical studies of multiple sclerosis in Japan. Neurology 26: 8-10, 1976.
4. Kuroiwa Y, Igata A, Itahara K, Koshijima S, Tsubaki T. Nationwide survey of multiple sclerosis in Japan. Clinical analysis of 1,084 cases. Neurology 25: 845-851, 1975.
5. Fukazawa T, Tashiro K, Hamada T, et al. Multiple sclerosis in Hokkaido, the northernmost island of Japan: prospective analyses of clinical features. Intern Med 31: 349-352, 1992.
6. Houzen H, Niino M, Kikuchi S, et al. The prevalence and clinical characteristics of MS in northern Japan. J Neurol Sci 211: 49-53, 2003.
7. Kira J, Kanai T, Nishimura Y, et al. Western versus Asian types of multiple sclerosis: immunogenetically and clinically distinct disorders. Ann Neurol 40: 569-574, 1996.
8. Yamasaki K, Horiuchi I, Minohara M, et al. HLA-DPB1*0501-associated opticospinal multiple sclerosis: clinical, neuroimaging and immunogenetic studies. Brain 122: 1689-1696, 1999.
9. Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13: 227-231, 1983.
10. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50: 121-127, 2001.
11. European Study Group on interferon beta-1b in secondary progressive MS. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. Lancet 352: 1491-1497, 1998.
12. McDonnell GV, Hawkins SA. Primary progressive multiple sclerosis: increasing clarity but many unanswered questions. J Neurol Sci 199: 1-15, 2002.
13. Confavreux C, Aimard G, Devic M. Course and prognosis of multiple sclerosis assessed by the computerized data processing of 349 patients. Brain 103: 281-300, 1980.
14. Thompson AJ, Polman CH, Miller DH, et al. Primary progressive multiple sclerosis. Brain 120: 1085-1096, 1997.
15. Bashir K, Whitaker JN. Clinical and laboratory features of primary progressive and secondary progressive MS. Neurology 53: 765-771, 1999.
16. Fukazawa T, Kikuchi S, Sasaki H, et al. Genomic HLA profiles of MS in Hokkaido, Japan: important role of DPB1*0501 allele. J Neurol 247: 175-178, 2000.
17. Cottrell DA, Kremenchutzky M, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 122: 625-639, 1999.
18. Ingle GT, Stevenson VL, Miller DH, Thompson AJ. Primary progressive multiple sclerosis: a 5-year clinical and MR study. Brain 126: 2528-2536, 2003.
19. Miller JR, Burke AM, Bever CT. Occurrence of oligoclonal bands in multiple sclerosis and other CNS diseases. Ann Neurol 13: 53-58, 1983.
20. Keren DF. Optimizing detection of oligoclonal bands in cerebrospinal fluid by use of isoelectric focusing with IgG immunoblotting. Am J Clin Pathol 120: 649-651, 2003.
21. Nakashima I, Fujihara K, Itoyama Y. Oligoclonal IgG bands in Japanese multiple sclerosis patients. J Neuroimmumol 101: 205-206, 1999.
22. Nakashima I, Fujihara K, Okita N, Takase S, Itoyama Y. Clinical and MRI study of brain stem and cerebellar involvement in Japanese patients with multiple sclerosis. J Neurol Neurosurg Psychiatry 67: 153-157, 1999.
23. Hao Q, Saida T, Matsui M, et al. Epidemiology and analysis of clinical features and MRI data in 238 patients with multiple sclerosis. Annual Report of the Neuroimmunological Disorders, Research Committee, Tokyo: The Ministry of Health and Welfare of Japan, 1999: 9-10 (in Japanese).